Lifemd (LFMD) reported $194M in revenue for fiscal 2025, +25.3% year on year. That ranks #2672 by revenue among 2853 SEC filers and #287 in Healthcare. It posted a net loss of −$11.2M for the same year. Revenue has grown 54.6% a year on average since 2012 ($673,778 then). The fiscal 2025 balance sheet shows $70.4M in total assets and $36.8M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $194M | +25.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $166M | +24.7% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$7.7M | +$12.7M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$11.2M | −$35.8M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $8.3M | −52.7% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.9M | +27.8% | FY20252025-12-31 |
| Total assetsAssets | $70.4M | −7.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $23.2M | +$32.2M | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $36.8M | +5.1% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $50.2M | −$8.9M | Open → |
| Q2 20262026-06-30 | $47.3M | −$7.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Lifemd, Inc.
- Ticker
- LFMD
- Exchange
- Nasdaq
- SIC classification
- Services-Offices & Clinics of Doctors of Medicine (8011)
- Fiscal year end
- 12-31
- CIK
- 0000948320
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KMar 10, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Si-BoneSIBN | $201M | −$18.9M |
| ValnevaVALN | $197M | −$130M |
| Strata Critical MedicalSRTA | $197M | $41.3M |
| LifemdLFMD | $194M | −$11.2M |
| Lakeland IndustriesLAKE | $193M | −$25.3M |
| BioteBTMD | $192M | $27.0M |
| Rhythm PharmaceuticalsRYTM | $190M | −$196,539 |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Lifemd — Key figures |url=https://companiesranked.com/en/company/lifemd |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Lifemd — Key figures. CompaniesRanked. https://companiesranked.com/en/company/lifemdBibTeX
@misc{companiesranked-en-company-lifemd-2026,
author = {{CompaniesRanked}},
title = {{Lifemd — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/lifemd}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001493152-26-009549 · March 10, 2026
{{cite web |title=Lifemd — Key figures — 10-K (0001493152-26-009549) |url=https://www.sec.gov/Archives/edgar/data/948320/000149315226009549/form10-k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-10}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.